You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

 

Online download statistics by month:

Online download statistics by month: November 2023 to September 2024

AbstractFullPdf
Nov 2023184010
Dec 20235708
Jan 20241601
Feb 20242404
Mar 20246404
Apr 20244205
May 20242004
Jun 20241800
Jul 20241603
Aug 20244804
Sep 20243202
Total521045